{"id":"tamiflu-verum","safety":{"commonSideEffects":[{"rate":"10","effect":"Nausea"},{"rate":"8","effect":"Vomiting"},{"rate":"2","effect":"Headache"},{"rate":"5","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL2108924","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oseltamivir (Tamiflu) is a prodrug that is converted in the body to its active form, which binds to and inhibits influenza neuraminidase. This enzyme normally cleaves sialic acid receptors on host cells, allowing newly formed virus particles to escape. By blocking this step, the drug traps viral particles on the cell surface and reduces transmission to neighboring cells, thereby shortening infection duration and reducing symptom severity.","oneSentence":"Tamiflu inhibits neuraminidase, an enzyme on the surface of influenza viruses, preventing viral release from infected cells and reducing viral spread.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:11:04.463Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of acute uncomplicated influenza A and B infection in patients ≥2 weeks of age"},{"name":"Prophylaxis of influenza A and B in patients ≥1 year of age"}]},"trialDetails":[{"nctId":"NCT01053377","phase":"PHASE4","title":"A Randomised Controlled Trial on the Effect of Post-exposure Oseltamivir Prophylaxis on Influenza Transmission in Nursing Homes","status":"UNKNOWN","sponsor":"National Institute for Public Health and the Environment (RIVM)","startDate":"2009-12","conditions":"Influenza","enrollment":900}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Tamiflu (verum)","genericName":"Tamiflu (verum)","companyName":"National Institute for Public Health and the Environment (RIVM)","companyId":"national-institute-for-public-health-and-the-environment-rivm","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tamiflu inhibits neuraminidase, an enzyme on the surface of influenza viruses, preventing viral release from infected cells and reducing viral spread. Used for Treatment of acute uncomplicated influenza A and B infection in patients ≥2 weeks of age, Prophylaxis of influenza A and B in patients ≥1 year of age.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}